RHEUMATOID ARTHRITIS
 
 
 OVERVIEW
 

Rheumatoid arthritis (RA) is traditionally considered a chronic, inflammatory autoimmune disorder that causes the immune system to attack the tissues of joints. Once triggered, the immune response causes inflammation of the synovium, leading to edema, vasodilation and infiltration by activated T-cells (mainly CD4 in nodular aggregates and CD8 in diffuse infiltrates). Early and intermediate molecular mediators of inflammation include tumor necrosis factor alpha (TNF-α), interleukins IL-1, IL-6, IL-8 and IL-15, transforming growth factor beta, fibroblast growth factor and platelet-derived growth factor. Biomarkers of the disease also includes the activation/upregulation of NK-kappaB (NFkB), Inducible Nitric Oxide Synthase (iNOS), Serum Amyloid A-1 (SAA-1), Eosinophil Peroxidase (Epx), Cyclooxygenase-2 (COX2) and others.

 

There is no known cure for rheumatoid arthritis and current treatments focus on alleviating symptoms. One of the possible reasons for the lack of treatments may be due to the limitations of the animal models that are available. There are a number of different models each with strengths and weaknesses when compared with the human aspects of the disease. The following is a summary of the models MIR has to offer:

MODEL
SPECIES
READOUT
DURATION
PROS
CONS

Collagen-Induced Arthritis (CIA)

Dark Agouti Rats

Incidence, Severity, Imaging, Histopathology, Client-Driven Analytes

4 Weeks

High Incidence of Disease. T-Cell Dependent. Response to TNF-type Agents.

Strain Limited.

LPS-Synchronized CIA

DBA/1 Mice

Incidence, Severity, Imaging, Histopathology, Client-Driven Analytes

7 Weeks

100% incidence. Joint Damage. Shorter than traditional CIA.

Strain Limited. Aggressive Disease.

Adjuvant-Induced Polyarthritis

Rats

Incidence, Severity, Imaging, Histopathology, Client-Driven Analytes

4 – 6 Wks

High incidence of disease. Joint damage. Steroid responsive. Acute phase protein response.

Lewis rats respond best. Aggressive disease.

Collagen Antibody Induced Arthritis (CAIA)

Mice

Incidence, Severity, Imaging, Histopathology, Client-Driven Analytes

10-18 Days

Rapid onset. Joint damage. Not strain limited.

Aggressive.

Custom Models

Rats/Mice

Client-Driven

Click here for larger image

 
 COLLAGEN INDUCED ARTHRITIS (CIA)

Collagen-induced arthritis (CIA) is an animal model of rheumatoid arthritis (RA) that is widely used to address questions of disease pathogenesis and to validate therapeutic targets. Collagen-induced arthritis models can be performed in both in mice or rats by immunization with heterologous type II collagen in adjuvant. Susceptibility to collagen-induced arthritis is strongly associated with major histocompatibility complex class II genes, and the development of arthritis is accompanied by a robust T-cell and B-cell response to type II collagen.

Pathological Features:

The chief pathological features of collagen-induced arthritis include a proliferative synovitis with infiltration of polymorphonuclear and mononuclear cells, pannus formation, cartilage degradation, erosion of bone, and fibrosis. As in human rheumatoid arthritis, pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b) and IL-6 are increased in collagen-induced arthritis. Biological therapies designed to interfere with these mediators are active in these models.

Measurements:

Disease activity is assessed by measuring swelling in the affected joints (paw volume or thickness) over time. Treatments can be assessed in either prophylactic or therapeutic testing paradigms. Additional measure of disease activity include evaluation of serum IL-1b, IL-6, C-reactive protein (CRP) or serum amyloid A (SAA), and erythrocyte sedimentation rate. Bone lesion scoring conducted by preclinical Positron Emission Tomography (preclinical PET). MIR typically measures all four paws for thickness and gives an average paw thickness for each animal at each timepoint. Animal body weights are typically taken 2 times per week.

General Outline of Study:

Collagen-induced arthritis can be induced in either rats or mice using bovine type II collagen. Prophylactic studies in rats are carried out over 28 days (50 days for mice), while therapeutic studies require a 14 day protocol (26 for mice).

Histology and Analytical Services :

MIR Preclinical Services has established strategic partners for histology, immunohistochemistry, Phamacokinetics, blood chemistries and other pertainent services that clients may request. Each strategic partner is a specialist in the area of interest and MIR Preclinical Services can offer these services as a part of its offerings.

Reports:

Each week clients receive an interim report that contains all the data for a current study up to that day. This contains data on body weights, changes in body weights over time, paw measurements, changes in paw measurements over time, clinical based scoring, daily census, comments, necropsy findings and summary graphics. Clients will also receive an email detailing each significant study milestone including when animals are ordered, when animals are injected with inflammatory agents, when treatment begins, when treatment ends and when the study ends. Final reports contain detail materials and methods, statistical analysis, publication quality tables and figures, popular enpoint calculations (paw thickness, peak swelling, time to peak swelling, clinical grade scoring, overall severity, AUC, etc.)and all raw data for the study. Custom endpoints and analyses can also be generated upon request. MIR Preclinical Services strives to have final reports to clients within 3 weeks of the euthanasia of the last animal on study for preclinical pharmacology experiments and between 5 to 7 weeks for extensive preclinical imaging studies (depending on size and imaging modality).

Imaging in Rat Collagen-Induced Arthritis :

MIR Preclinical Services is the leading contract research organization in the application of preclinical imaging to preclinical models of cancer and arthritis. MIR has preclinical computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and biophotonic imaging capabilities. MIR Preclinical Services owns all of their own imaging equipment and operates this equipment on site. All of the company's imaging equipment is state-of-the-art and designed exclusively for small animals.

Control Rats
Methotrexate at 0.3mg/kg
Dexamethasone at 1.0mg/kg
 
 LPS SYNCHRONIZED CIA
 

Lipopolysaccharide (LPS) is an endotoxin that binds CD14/TLR4/MD2 receptor complex and induces a strong response from the immune system. This dramatically increases the secretion of pro-inflammatory cytokines in many cell types, but especially in macrophages. This model enhances CIA and produces a 100% incidence of arthritic symptoms in mice within 24 to 48 hours after LPS is injected. Unlike the CIA model, arthritis progresses rapidly, within a few hours compared to weeks.

Pathological Features:

Simailr to collagen-induced arthritis (CIA) described above.

Measurements:

Simailr to collagen-induced arthritis (CIA) described above.

General Outline of Study:

LPS synchronized c ollagen-induced arthritis can be induced in mice using bovine type II collagen. Prophylactic studies in rats are carried out over 50 days, while therapeutic studies require a 26 day protocol. LPS synchronizes the development of the disease so the study tends to have less overall variability than standard CIA mice models.

 
 ADJUVANT-INDUCED POLYARTHRITIS
 

This model is currently under development. Please call to inquire on availability.

 
 mAB-INDUCED ARTHRITIS
 

This model is currently under development. Please call to inquire on availability.

 
 CUSTOM MODELS
 

MIR is a contract research organization (CRO) that is happy to collaborate with clients to develop new models for clients’ use. If we do not have a model that is commercially available, we can develop the model for clients use at a reduced or shared cost, depending on demand for that model. We are also happy to performed client directed research if it is within our capabilities. MIR has an active internal research and development program to develop new client offering. In regards to imaging models, MIR’s license to utilize luciferase expressing mice developed by Xenogen can be utilized to access the effects of candidate compounds and treatments on the expression of genes under the control of a variety of promoters including NF-kB, iNOS, COX-II and others. MIR's extensive experience in the area of inflammation and drug discovery allow the company to offer specialized studies. In addition to providing premier contract studies, all of MIR senior staff are seasoned veterans in drug discovery and offer expert consultation as part of our services. Please feel free to inquire on new models under development. All protocols performed by MIR must be approved by MIR’s animal care and use committee and in line with all NIH and OLAW guidelines.

 
 
 
800 Technology Drive• Ann Arbor, Michigan 48108
Phone: 734.821.1063 Fax:734.821.1066
 
Click here for CIA flier
 
updated:  3/19/08